At this moment of the pandemic, a very critical point is to know if each of us is immunised and at the same time if is contagious or no. To know if people are immunised against COVID-19 is essential information to be able to undo this state of quarantine in which we are immersed. Only people who have been infected, but are already non-contagious, could return to their normal lives, allowing a progressive return to our previous routine. For this reason, it is essential to analyse the antibody load that each person presents. Therefore, the combined of an RT-PCR + a rapid serological test (for antibodies detection) is what should be imposed as a requirement to return to normality. First, a serological test could tell us if we have antibodies against the virus and only in the case we have specific antibodies in our blood, a confirmation by RT-PCR will be required to ensure that we are not infectious. A positive IgG with an already negative IgM, practically wouldn´t require confirmation by RT-PCR, but sometimes the virus or its proteins are maintained in blood for longer time. Thus, there exist different possibilities:
(...)
View more
4/6/2020
On 6th April, 2020 , Rekom Biotech appeared in the newspaper IDEAL, where were shown the different projects that exist in Granada (Spain) about COVID-19. One of them is the project of Rekom Biotech, which consists of designing and producing recombinant antigens focused on the spike protein of the virus, as well as a multi-epitope chimera which improve its antigenic capacity. They are being expressed in bacteria and in yeast. "This last expression system could give an antigen with better antigenic characteristics, due to its ability to mimic the native folding of the produced heterologous protein. This would lead to a better biomarker and, consequently, a faster and more accurate diagnostic. We are working on improving the antigenic and physicochemical characteristics of the antigen, so that we can improve its versatility and can be used in the different rapid in vitro diagnostic platforms on the market", said Dr. Ana Camacho, CEO of Rekom Biotech.
(...)
View more
3/25/2020
On the last 25th March, 2020, Rekom Biotech appeared in the newspaper IDEAL, where more than 30 new Andalusian research projects against the coronavirus were revealed. Companies, research centers, the universities of Granada and Jaén and the new IDEA Agency have presented their initiatives in an online forum organized by the Health Sciences Technology Park. Rekom Biotech presented its work related with the design and development of raw material for rapid tests for detection of COVID-19.
The news was also echoed in newspapers such as Granada Hoy, Diario Sur and Granada Salud.
On 31 December 2019, WHO was informed of a cluster of cases of pneumonia of unknown cause detected in Wuhan City, Hubei Province of China. The coronavirus disease (COVID-2019) was identified as the causative virus by Chinese authorities on 7 January. As part of WHO’s response to the outbreak, the R&D has been activated to accelerate diagnostics, vaccines and therapeutics for this novel coronavirus.
Figure 1. Coronavirus, 2020. Illustration by David S. Goodsell, RCSB Protein Data Bank doi: 10.2210/rcsb_pdb/goodsell-gallery-019
(...)
View more
Native antigens are extracted in their natural form from the corresponding source. Recombinant antigens are instead manufactured artificially. A common method of achieving this is to transform the heterologous expression system with a vector expressing the protein of interest, following which the expressed protein can be purified from the culture broth.
(...)
View more
Buy direct from the manufacturer
